Predicted interactions involving protein NR4A2, NOT, NURR1, TINUR: Nuclear receptor subfamily 4 group A member 2 (IPI00018033) that score above 1.0

Click on the protein name for more information about the protein.

The Score column is the predicted score of interaction between the two proteins

Click on the Evidence link to view a breakdown of the information about the predicted interaction.

Key
Module ScoreDatabases
Where interaction is observed in another database a link is provided:

Protein 1 (?)Protein 2 (?) Name of Protein 2 Module Scores (?) Scores (?) Evidence (?) Database (?)
NR4A2 RPS6KA2 RPS6KA2, RSK3: Ribosomal protein S6 kinase alpha-2 1.67E3 Evidence
NR4A2 RPS6KA1 RPS6KA1, RSK1: Ribosomal protein S6 kinase alpha-1 1.32E3 Evidence
NR4A2 MAP2K3 N/A 255.0 Evidence
NR4A2 RPS6KA3 RPS6KA3, ISPK1, RSK2: Ribosomal protein S6 kinase alpha-3 181.0 Evidence
NR4A2 TP53 TP53, P53: Cellular tumor antigen p53 82.10 Evidence
NR4A2 CREBBP CREBBP, CBP: CREB-binding protein 56.70 Evidence
NR4A2 JUN JUN: Transcription factor AP-1 26.00 Evidence
NR4A2 MAPK3 MAPK3, ERK1, PRKM3: Mitogen-activated protein kinase 3 20.40 Evidence
NR4A2 HIF1A HIF1A, MOP1: Hypoxia-inducible factor 1 alpha 20.40 Evidence
NR4A2 PPARA PPARA, NR1C1, PPAR: Peroxisome proliferator-activated receptor alpha 18.10 Evidence
NR4A2 JUND JUND: Transcription factor jun-D 16.50 Evidence
NR4A2 GCN5L2 GCN5L2, GCN5, HGCN5: General control of amino acid synthesis protein 5-like 2 13.60 Evidence
NR4A2 ESR1 ESR1, ESR, NR3A1: Estrogen receptor 12.90 Evidence
NR4A2 TAL2 TAL2: T-cell acute lymphocytic leukemia protein 2 10.30 Evidence
NR4A2 HDAC4 HDAC4, KIAA0288: Histone deacetylase 4 10.30 Evidence
NR4A2 CEBPB CEBPB, TCF5, PP9092: CCAAT/enhancer-binding protein beta 8.22 Evidence
NR4A2 UBTF UBTF, UBF, UBF1: Nucleolar transcription factor 1 7.43 Evidence
NR4A2 NR2F1 NR2F1, EAR3, ERBAL3, TFCOUP1: COUP transcription factor 1 6.54 Evidence
NR4A2 DUSP1 DUSP1, CL100, MKP1, PTPN10, VH1: Dual specificity protein phosphatase 1 6.45 Evidence
NR4A2 RAVER1 RAVER1, KIAA1978: Ribonucleoprotein PTB-binding 1 6.24 Evidence
NR4A2 YWHAB YWHAB: 14-3-3 protein beta/alpha 6.16 Evidence
NR4A2 MAPK8 MAPK8, JNK1, PRKM8: Mitogen-activated protein kinase 8 5.87 Evidence
NR4A2 TCF3 TCF3, E2A, ITF1: Transcription factor E2-alpha 5.86 Evidence
NR4A2 TAL1 TAL1, SCL, TCL5: T-cell acute lymphocytic leukemia protein 1 5.86 Evidence
NR4A2 FKBP1A FKBP1A, FKBP1, FKBP12: FK506-binding protein 1A 5.86 Evidence
NR4A2 PSMC1 PSMC1: 26S protease regulatory subunit 4 5.27 Evidence
NR4A2 CDC23 CDC23: Cell division cycle protein 23 homolog 5.27 Evidence
NR4A2 CASP9 CASP9, MCH6: Caspase-9 precursor 4.78 Evidence
NR4A2 MAP2K6 MAP2K6, MEK6, MKK6, PRKMK6: Dual specificity mitogen-activated protein kinase ki 4.63 Evidence
NR4A2 STAT5A STAT5A, STAT5: Signal transducer and activator of transcription 5A 4.58 Evidence
NR4A2 MAP3K7 MAP3K7, TAK1: Mitogen-activated protein kinase kinase kinase 7 4.01 Evidence
NR4A2 NFIA NFIA, RP5-902P15.1-003, hCG_2032260: Nuclear factor I/A 3.88 Evidence
NR4A2 MKNK1 MKNK1, MNK1: MAP kinase-interacting serine/threonine-protein kinase 1 3.47 Evidence
NR4A2 DUSP6 DUSP6, MKP3, PYST1: Dual specificity protein phosphatase 6 3.47 Evidence
NR4A2 ADRBK1 ADRBK1, BARK, BARK1, GRK2: Beta-adrenergic receptor kinase 1 3.45 Evidence
NR4A2 IRAK1 IRAK1, IRAK: Interleukin-1 receptor-associated kinase 1 3.45 Evidence
NR4A2 MINK1 MAP4K6, MINK1, MINK: Misshapen-like kinase 1 3.34 Evidence
NR4A2 RAB4A N/A 3.34 Evidence
NR4A2 GAB1 GAB1: GRB2-associated-binding protein 1 3.07 Evidence
NR4A2 IRS1 IRS1: Insulin receptor substrate 1 3.07 Evidence
NR4A2 TOP2B N/A 3.07 Evidence
NR4A2 DUSP3 DUSP3, VHR: Dual specificity protein phosphatase 3 3.07 Evidence
NR4A2 PSMC5 PSMC5, SUG1: 26S protease regulatory subunit 8 3.01 Evidence
NR4A2 PRKAA2 PRKAA2, AMPK, AMPK2: 5'-AMP-activated protein kinase catalytic subunit alpha-2 2.99 Evidence
NR4A2 RPS6KA4 RPS6KA4, MSK2: Ribosomal protein S6 kinase alpha-4 2.99 Evidence
NR4A2 PDPK1 PDPK1, PDK1: 3-phosphoinositide-dependent protein kinase 1 2.99 Evidence
NR4A2 SMAD2 SMAD2, MADH2, MADR2: Mothers against decapentaplegic homolog 2 2.75 Evidence
NR4A2 ETS1 ETS1, EWSR2: Protein C-ets-1 2.75 Evidence
NR4A2 MAP3K14 MAP3K14, NIK: Mitogen-activated protein kinase kinase kinase 14 2.49 Evidence
NR4A2 THRA THRA, ERBA1, NR1A1, THRA1, THRA2: Thyroid hormone receptor alpha 2.43 Evidence
NR4A2 SYK SYK: Tyrosine-protein kinase SYK 2.33 Evidence
NR4A2 HSF1 HSF1, HSTF1: Heat shock factor protein 1 2.28 Evidence
NR4A2 MAP2K1 MAP2K1, MEK1, PRKMK1: Dual specificity mitogen-activated protein kinase kinase 1 2.23 Evidence
NR4A2 ELK1 ELK1: ETS domain-containing protein Elk-1 2.23 Evidence
NR4A2 ALK RARA, NR1B1: Retinoic acid receptor alpha 2.00 Evidence
NR4A2 HSPB8 HSPB8, CRYAC, PP1629, E2IG1, HSP22: Heat shock protein beta-8 1.96 Evidence
NR4A2 PRKCE PRKCE, PKCE: Protein kinase C epsilon type 1.77 Evidence
NR4A2 AMPH AMPH, AMPH1: Amphiphysin 1.71 Evidence
NR4A2 PTPN7 N/A 1.71 Evidence
NR4A2 RAF1 RAF1, RAF: RAF proto-oncogene serine/threonine-protein kinase 1.64 Evidence
NR4A2 NR1H2 NR1H2, LXRB, NER, UNR: Oxysterols receptor LXR-beta 1.62 Evidence
NR4A2 PSMA3 PSMA3, PSC8: Proteasome subunit alpha type-3 1.53 Evidence
NR4A2 SPTBN1 SPTBN1, SPTB2: Spectrin beta chain, brain 1 1.53 Evidence
NR4A2 DAPK1 DAPK1, DAPK: Death-associated protein kinase 1 1.41 Evidence
NR4A2 LYN LYN: Tyrosine-protein kinase Lyn 1.34 Evidence
NR4A2 SNCG SNCG, BCSG1, PERSYN, PRSN: Gamma-synuclein 1.30 Evidence
NR4A2 RXRB RXRB, NR2B2: Retinoic acid receptor RXR-beta 1.24 Evidence
NR4A2 HNRPH3 HNRPH3: Heterogeneous nuclear ribonucleoprotein H3 1.18 Evidence
NR4A2 EWSR1 EWSR1, EWS: RNA-binding protein EWS 1.18 Evidence
NR4A2 MAP2K2 MAP2K2, MEK2, MKK2, PRKMK2: Dual specificity mitogen-activated protein kinase ki 1.17 Evidence
NR4A2 PTPN11 N/A 1.14 Evidence
NR4A2 PEA15 PEA15: Astrocytic phosphoprotein PEA-15 1.12 Evidence
NR4A2 MGMT MGMT: Methylated-DNA--protein-cysteine methyltransferase 1.01 Evidence
NR4A2 PLCB1 PLCB1, KIAA0581: 1-phosphatidylinositol-4,5-bisphosphate phosphodiesterase beta- 1.00 Evidence
NR4A2 STMN2 STMN2, SCG10, SCGN10: Stathmin-2 1.00 Evidence